Zogenix, Inc. (ZGNX) to Post Q3 2018 Earnings of ($0.82) Per Share, Piper Jaffray Companies Forecasts

Zogenix, Inc. (NASDAQ:ZGNX) – Research analysts at Piper Jaffray Companies issued their Q3 2018 EPS estimates for Zogenix in a research note issued on Monday, November 5th. Piper Jaffray Companies analyst D. Brill anticipates that the company will post earnings of ($0.82) per share for the quarter. Piper Jaffray Companies has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for Zogenix’s Q4 2018 earnings at ($0.94) EPS, FY2018 earnings at ($3.46) EPS, Q1 2019 earnings at ($0.80) EPS, Q2 2019 earnings at ($0.89) EPS, Q3 2019 earnings at ($0.71) EPS, Q4 2019 earnings at ($0.76) EPS, FY2019 earnings at ($3.18) EPS, FY2020 earnings at ($0.11) EPS, FY2021 earnings at $4.33 EPS and FY2022 earnings at $6.54 EPS.

Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($1.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.20). During the same quarter in the previous year, the firm posted ($1.68) EPS.

Several other research firms have also commented on ZGNX. Stifel Nicolaus increased their price objective on shares of Zogenix from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, July 13th. BidaskClub lowered shares of Zogenix from a “hold” rating to a “sell” rating in a research note on Friday, August 17th. Leerink Swann reiterated an “outperform” rating on shares of Zogenix in a research note on Friday, October 19th. Empire increased their price objective on shares of Zogenix from $57.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, July 31st. Finally, Mizuho reiterated a “buy” rating and issued a $69.00 price objective on shares of Zogenix in a research note on Friday, August 24th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $71.90.

NASDAQ:ZGNX opened at $43.30 on Wednesday. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.77 and a beta of 1.86. Zogenix has a 52 week low of $32.40 and a 52 week high of $62.75.

In other news, EVP Gail M. Farfel sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $47.58, for a total transaction of $333,060.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gail M. Farfel sold 6,961 shares of the firm’s stock in a transaction that occurred on Thursday, October 4th. The stock was sold at an average price of $43.23, for a total transaction of $300,924.03. Following the sale, the executive vice president now owns 14,104 shares of the company’s stock, valued at approximately $609,715.92. The disclosure for this sale can be found here. Company insiders own 5.00% of the company’s stock.

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Zogenix during the 3rd quarter worth approximately $109,000. BlueMountain Capital Management LLC purchased a new position in Zogenix in the 2nd quarter valued at approximately $104,000. FNY Investment Advisers LLC grew its stake in Zogenix by 3,900.0% in the 3rd quarter. FNY Investment Advisers LLC now owns 3,000 shares of the company’s stock valued at $148,000 after buying an additional 2,925 shares in the last quarter. Prudential Financial Inc. purchased a new position in Zogenix in the 3rd quarter valued at approximately $219,000. Finally, Public Employees Retirement Association of Colorado purchased a new position in Zogenix in the 3rd quarter valued at approximately $226,000.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Recommended Story: Fundamental Analysis – How It Helps Investors

Earnings History and Estimates for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply